Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
New Insights into Targeted Drugs for Breast Cancer (Volume II)
share announcement

New Insights into Targeted Drugs for Breast Cancer (Volume II)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 1590

Special Issue Editors

Dr. Jennifer Diamond

E-Mail Website
Guest Editor
University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, 12801 E 17th Ave, MS8117, Aurora, CO 80045, USA
Interests: triple-negative breast cancer; phase I clinical trials; drug resistance
Special Issues, Collections and Topics in MDPI journals
Dr. Jennifer Richer

E-Mail Website
Guest Editor
Department of Pathology, Anschutz Medical Campus, University of Colorado, Aurora, CO 80045, USA
Interests: hormone receptor-positive breast cancer; androgen receptor inhibitors in breast cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the Special Issue, "New Insights into Targeted Drugs for Breast Cancer" (https://www.mdpi.com/journal/cancers/special_issues/TDBC).

Over the last decade we have seen a rapid increase in targeted therapies for breast cancer, including in hormone receptor (HR)-positive, HER2+ and triple-negative breast cancer (TNBC). The development of CDK4/6, PI3K and new SERDs in HR+ breast cancer, new HER2-targeted therapies (including small-molecule inhibitors, ADCs and monoclonal antibodies), and Trop2-ADCs and PARP inhibitors for TNBC and BRCA-mutated cancers, respectively, have changed the way we treat patients with all breast cancer subtypes. These advances have improved patient outcomes and given clinicians more treatment options.

For this Special Issue of Cancers, we welcome original and review papers focused on targeted therapies in breast cancer, including novel rational combinations and strategies to overcome treatment resistance.  While this Special Issue is not focused on immunotherapy, works focused on combination strategies including immunotherapy and targeted therapies are also encouraged.

Dr. Jennifer Diamond
Dr. Jennifer Richer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • targeted therapies
  • treatment resistance
  • HER2
  • hormone receptor-positive
  • triple-negative breast cancer

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

25 pages, 5492 KiB  
Article
Molecular Atlas of HER2+ Breast Cancer Cells Treated with Endogenous Ligands: Temporal Insights into Mechanisms of Trastuzumab Resistance
by Kavitha Mukund, Jackelyn A. Alva-Ornelas, Adam L. Maddox, Divya Murali, Darya Veraksa, Andras Saftics, Jerneja Tomsic, David Frankhouser, Meagan Razo, Tijana Jovanovic-Talisman, Victoria L. Seewaldt and Shankar Subramaniam
Cancers 2024, 16(3), 553; https://doi.org/10.3390/cancers16030553 - 27 Jan 2024
Viewed by 1242
Abstract
Trastuzumab therapy in HER2+ breast cancer patients has mixed success owing to acquired resistance to therapy. A detailed understanding of downstream molecular cascades resulting from trastuzumab resistance is yet to emerge. In this study, we investigate the cellular mechanisms underlying acquired resistance using [...] Read more.
Trastuzumab therapy in HER2+ breast cancer patients has mixed success owing to acquired resistance to therapy. A detailed understanding of downstream molecular cascades resulting from trastuzumab resistance is yet to emerge. In this study, we investigate the cellular mechanisms underlying acquired resistance using trastuzumab-sensitive and -resistant cancer cells (BT474 and BT474R) treated with endogenous ligands EGF and HRG across time. We probe early receptor organization through microscopy and signaling events through multiomics measurements and assess the bioenergetic state through mitochondrial measurements. Integrative analyses of our measurements reveal significant alterations in EGF-treated BT474 HER2 membrane dynamics and robust downstream activation of PI3K/AKT/mTORC1 signaling. EGF-treated BT474R shows a sustained interferon-independent activation of the IRF1/STAT1 cascade, potentially contributing to trastuzumab resistance. Both cell lines exhibit temporally divergent metabolic demands and HIF1A-mediated stress responses. BT474R demonstrates inherently increased mitochondrial activity. HRG treatment in BT474R leads to a pronounced reduction in AR expression, affecting downstream lipid metabolism with implications for treatment response. Our results provide novel insights into mechanistic changes underlying ligand treatment in BT474 and BT474R and emphasize the pivotal role of endogenous ligands. These results can serve as a framework for furthering the understanding of trastuzumab resistance, with therapeutic implications for women with acquired resistance. Full article
(This article belongs to the Special Issue New Insights into Targeted Drugs for Breast Cancer (Volume II))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop